triazoles has been researched along with Arthritis, Psoriatic in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Besuyen, R; Coates, LC; Gao, J; Gossec, L; Hendrikx, T; Leung, YY; Meuleners, L; Ogdie, A; Orbai, AM; Tasset, C; Tillett, W; Trivedi, M | 1 |
| Aletaha, D; Baraliakos, X; Boehncke, WH; de Wit, M; Dörner, T; Dougados, M; Emery, P; Fleischmann, RM; Geissler, K; Isaacs, JD; Kerschbaumer, A; Kremer, J; Lee, EB; Maksymowych, WP; McInnes, I; Nash, P; Pope, JE; Smolen, JS; Stoffer-Marx, M; Takeuchi, T; Tam, LS; Tanaka, Y; Trauner, M; van den Bosch, F; van der Heijde, D; Voshaar, M; Westhovens, R; Winthrop, KL; Xavier, R | 1 |
| Adas, M; Bechman, K; Cope, AP; Galloway, JB; Mootoo, A; Norton, S; Patel, V; Qureshi, S; Rampes, S; Yates, M | 1 |
| Coates, LC; White, JPE | 1 |
| Fearon, U; Flynn, K; Hanlon, MM; Marzaioli, V; O'Brien, A; Veale, DJ; Wade, SC | 1 |
| Abi-Saab, W; Besuyen, R; Coates, LC; Dudek, A; Gladman, DD; Greer, JM; Harrison, P; Helliwell, PS; Kunder, R; Mease, P; Meuleners, L; Mozaffarian, N; Rychlewska-Hanczewska, A; Stanislavchuk, M; Tasset, C; Van den Bosch, F; Van der Aa, A | 1 |
| Gadina, M; O'Shea, JJ | 1 |
| Ahern, T; Kirby, B; Lynch, M; O'Shea, D; Tobin, AM | 1 |
| Camargo, JF; Cho-Vega, JH; Yakoub, D | 1 |
| Al-Mossawi, MH; Bowness, P; Brennan, PE; de Wit, J; Fedorov, O; Hammitzsch, A; Hay, DA; Knapp, S; Martinez, FO; Müller, S; O'Mahony, A; Tallant, C; Vecellio, M; Wells, C; Wordsworth, P | 1 |
| Schwetz, BA | 1 |
3 review(s) available for triazoles and Arthritis, Psoriatic
| Article | Year |
|---|---|
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Topics: Adamantane; Advisory Committees; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Cytokines; Drug Therapy, Combination; Europe; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Niacinamide; Piperidines; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Rheumatology; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles | 2021 |
Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Heterocyclic Compounds, 3-Ring; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Piperidines; Psoriasis; Pulmonary Embolism; Purines; Pyrazoles; Pyridines; Pyrimidines; Randomized Controlled Trials as Topic; Risk; Spondylarthropathies; Spondylitis, Ankylosing; Sulfonamides; Triazoles; Venous Thromboembolism; Venous Thrombosis | 2021 |
JAK1 selective inhibitors for the treatment of spondyloarthropathies.
Topics: Arthritis, Psoriatic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyridines; Spondylarthropathies; Spondylitis, Ankylosing; Triazoles | 2021 |
2 trial(s) available for triazoles and Arthritis, Psoriatic
| Article | Year |
|---|---|
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
Topics: Adaptation, Psychological; Arthritis, Psoriatic; Double-Blind Method; Fatigue; Humans; Janus Kinase Inhibitors; Least-Squares Analysis; Minimal Clinically Important Difference; Pain; Physical Functional Performance; Psoriasis; Pyridines; Quality of Life; Sleep Wake Disorders; Social Behavior; Treatment Outcome; Triazoles | 2020 |
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Topics: Accidental Falls; Antirheumatic Agents; Arthritis, Psoriatic; Double-Blind Method; Drug Therapy, Combination; Female; Headache; Hip Fractures; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Male; Middle Aged; Nasopharyngitis; Opportunistic Infections; Pneumonia; Pyridines; Severity of Illness Index; Triazoles | 2018 |
6 other study(ies) available for triazoles and Arthritis, Psoriatic
| Article | Year |
|---|---|
Targeting JAK-STAT Signalling Alters PsA Synovial Fibroblast Pro-Inflammatory and Metabolic Function.
Topics: Adamantane; Adult; Aged; Arthritis, Psoriatic; Azetidines; Cells, Cultured; Female; Fibroblasts; Heterocyclic Compounds, 3-Ring; Humans; Inflammation; Janus Kinase Inhibitors; Janus Kinases; Male; Middle Aged; Niacinamide; Purines; Pyrazoles; Pyridines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Synovial Membrane; Triazoles | 2021 |
Selective Janus kinase inhibitors come of age.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Pyridines; Triazoles | 2019 |
Sitagliptin for severe psoriasis.
Topics: Aged; Arthritis, Psoriatic; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole.
Topics: Antifungal Agents; Arthritis, Psoriatic; Debridement; Dermatomycoses; Diabetes Complications; Etanercept; Female; Humans; Immunosuppressive Agents; Middle Aged; Mucormycosis; Prednisone; Treatment Outcome; Triazoles; Wounds and Injuries | 2015 |
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
Topics: Adult; Aged; Arthritis, Psoriatic; Azepines; Benzimidazoles; Calorimetry; CD4-Positive T-Lymphocytes; Cells, Cultured; Crystallography, X-Ray; Drug Evaluation, Preclinical; Female; Gene Expression Regulation; Humans; Immunosuppressive Agents; Interleukin-17; Isoxazoles; Kinetics; Male; Middle Aged; Models, Molecular; Molecular Structure; p300-CBP Transcription Factors; Protein Conformation; Protein Structure, Tertiary; Recombinant Proteins; Spondylitis, Ankylosing; Structure-Activity Relationship; Th17 Cells; Triazoles | 2015 |
From the Food and Drug Administration.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Arthritis, Psoriatic; Benzamides; Chemical and Drug Induced Liver Injury; Cyclohexanones; Enzyme Inhibitors; Etanercept; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunoglobulin G; Infant; Liver Failure; Nitrobenzoates; Orphan Drug Production; Piperazines; Pyrimidines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Triazoles; Tyrosinemias; United States; United States Food and Drug Administration | 2002 |